Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TELA Bio (TELA) Cash & Equivalents (2018 - 2025)

TELA Bio (TELA) has 8 years of Cash & Equivalents data on record, last reported at $29.7 million in Q3 2025.

  • For Q3 2025, Cash & Equivalents rose 71.74% year-over-year to $29.7 million; the TTM value through Sep 2025 reached $29.7 million, up 71.74%, while the annual FY2024 figure was $52.7 million, 12.71% up from the prior year.
  • Cash & Equivalents reached $29.7 million in Q3 2025 per TELA's latest filing, down from $35.0 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $65.8 million in Q1 2021 and bottomed at $17.3 million in Q3 2024.
  • Average Cash & Equivalents over 5 years is $43.3 million, with a median of $42.8 million recorded in 2025.
  • Peak YoY movement for Cash & Equivalents: soared 135.4% in 2023, then plummeted 70.27% in 2024.
  • A 5-year view of Cash & Equivalents shows it stood at $43.9 million in 2021, then fell by 4.35% to $42.0 million in 2022, then grew by 11.21% to $46.7 million in 2023, then rose by 12.71% to $52.7 million in 2024, then plummeted by 43.59% to $29.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $29.7 million in Q3 2025, $35.0 million in Q2 2025, and $42.8 million in Q1 2025.